Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
31 Leser
Artikel bewerten:
(0)

Omnis Health Introduces EmbraceEVO' -- Blood Glucose Monitoring System

NASHVILLE, Tenn., May 15, 2014 /PRNewswire/ -- Omnis Health, a value leader in diabetes monitoring systems, today announced the launch of the new EmbraceEVO', a blood glucose meter with a sleek, compact design. The EmbraceEVO is uniquely available as an affordable all-in-one starter kit for value and convenience.

The EmbraceEVO(TM) blood glucose meter with a sleek, compact design, is uniquely available as an affordable all-in-one starter kit for value and convenience.

"Our company is committed to delivering healthcare innovations and value to both patients and supply partners. We are proud to be offering this cost-effective system that will benefit distributors, pharmacists and consumers alike," said Rob Burton, president of Omnis Health. "The EmbraceEVO meter and test strips are positioned to provide end-users with an affordable cash-pay option that, in many cases, would be less than a co-pay through Medicare or third-party commercial insurance."

The EmbraceEVO Monitoring Kit is pre-packaged with meter, 50 test strips, lancets, a lancing device and everything a patient needs to begin testing. Utilizing Omnis Heath's proprietary Instant Three Step Verification test strip technology, EmbraceEVO provides accurate results in six seconds.

The EmbraceEVO meter has a compact design with a large display and easy-to-read menu icons. It automatically stores up to 300 test and control results with date and time, and allows for 7-, 14- and 30-day averaging so patients and their healthcare providers can effectively track and control blood glucose levels.

According to the National Institutes of Health, there are more than 25.8 million Americans living with diabetes, 8.3 percent of the U.S. population. The number of people diagnosed with diabetes has risen from 1.5 million in 1958 to 18.8 million in 2010, an increase of epidemic proportions. Diabetes is a group of diseases marked by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Diabetes can lead to serious complications and premature death, but people with diabetes can take steps to control the disease and lower the risk of complications.

Omnis Health is committed to providing the highest quality products including the Embrace® family of blood glucose monitors. A value leader in the industry, we are committed to helping people manage their overall health. Our deep understanding of diabetes and the challenges facing people with diabetes allows us to adapt to the ever-changing healthcare environment and deliver timely, dependable and affordable blood glucose monitoring systems. Omnis Health is a trusted partner for durable medical equipment providers, wholesale distributors, medical professionals, and retailers alike. Visit www.omnishealth.com for more information.

Photo - http://photos.prnewswire.com/prnh/20140515/88229

SOURCE Omnis Health

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.